In humans, one study reported an increase in BP over 2 h from healthy subjects following a single administration of GLP-1 (136), while another reported that chronic administration of GLP-1 analogs to patients with metabolic syndrome led to a reduction in BP [reviewed in (29, 137, 138)]. Here, GLP1R is linked to metabolic syndrome.